Abstract

To explore the clinical effect of travoprost and timolol eye drops for senile glaucoma. This study selected 88 individuals having senile glaucoma admitted to the Affiliated Hospital of Weifang Medical University hospital for treatment between January 2020 and January 2022. Depending on treatment regimens, they were assigned to an observation group who were given travoprost (n=47) and control group who were given timolol eye drops (n=41). The therapeutic effects, visual field defects, 24 h peak intraocular pressure, binocular optic disc parameters, adverse effects and quality of life of the two groups were analyzed. Patients in the observation group showed notably better treatment outcomes when compared with the control patients. Obvious post-treatment improvements of visual field defects, 24 h peak intraocular pressure, binocular optic disc parameters and quality of life were observed in both groups, especially in the observation group; no significant inter-group difference was determined in adverse effects. Travoprost is superior to timolol eye drops to treat primary glaucoma in older adults, which can effectively ameliorate intraocular pressure and visual field defects, with less adverse effects and high safety. Its clinical application can be beneficial and is therefore recommended to be further popularized clinically.